Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 8;6(4):211.
doi: 10.3390/jof6040211.

COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?

Amir Arastehfar  1 , Agostinho Carvalho  2   3 , M Hong Nguyen  4 , Mohammad Taghi Hedayati  5 , Mihai G Netea  6   7   8 , David S Perlin  1 , Martin Hoenigl  9   10   11
Affiliations
Review

COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?

Amir Arastehfar et al. J Fungi (Basel). .

Abstract

The recent global pandemic of COVID-19 has predisposed a relatively high number of patients to acute respiratory distress syndrome (ARDS), which carries a risk of developing super-infections. Candida species are major constituents of the human mycobiome and the main cause of invasive fungal infections, with a high mortality rate. Invasive yeast infections (IYIs) are increasingly recognized as s complication of severe COVID-19. Despite the marked immune dysregulation in COVID-19, no prominent defects have been reported in immune cells that are critically required for immunity to Candida. This suggests that relevant clinical factors, including prolonged ICU stays, central venous catheters, and broad-spectrum antibiotic use, may be key factors causing COVID-19 patients to develop IYIs. Although data on the comparative performance of diagnostic tools are often lacking in COVID-19 patients, a combination of serological and molecular techniques may present a promising option for the identification of IYIs. Clinical awareness and screening are needed, as IYIs are difficult to diagnose, particularly in the setting of severe COVID-19. Echinocandins and azoles are the primary antifungal used to treat IYIs, yet the therapeutic failures exerted by multidrug-resistant Candida spp. such as C. auris and C. glabrata call for the development of new antifungal drugs with novel mechanisms of action.

Keywords: candidemia; candiduria; mycobiome; oral candidiasis.

PubMed Disclaimer

Conflict of interest statement

M.H. received research funding by Gilead and Pfizer. D.S.P. receives research support and/or serves on advisory boards for Amplyx, Cidara, Scynexis, N8 Medical, Merck, Regeneron, and Pfizer. He also has a patent covering the detection of fungal species and drug resistance, as well as a pending patent on COVID-19 detection licensed to T2 Biosystems. A.C. was supported by the Fundação para a Ciência e a Tecnologia (FCT) (CEECIND/03628/2017 and PTDC/MED-GEN/28778/2017). Additional support was provided by FCT (UIDB/50026/2020 and UIDP/50026/2020), the Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement through the European Regional Development Fund (ERDF) (NORTE-01-0145-FEDER-000013 and NORTE-01-0145-FEDER-000023), the European Union’s Horizon 2020 research and innovation program under grant agreement no. 847507, and the “la Caixa” Foundation (ID 100010434) and FCT under the agreement LCF/PR/HP17/52190003.

References

    1. Hallen-Adams H.E., Suhr M.J. Fungi in the healthy human gastrointestinal tract. Virulence. 2017;8:352–358. doi: 10.1080/21505594.2016.1247140. - DOI - PMC - PubMed
    1. Rolling T., Hohl T.M., Zhai B. Minority report: The intestinal mycobiota in systemic infections. Curr. Opin. Microbiol. 2020;56:1–6. doi: 10.1016/j.mib.2020.05.004. - DOI - PMC - PubMed
    1. Azoulay E., Timsit J.-F., Tafflet M., De Lassence A., Darmon M., Zahar J.-R., Adrie C., Garrouste-Orgeas M., Cohen Y., Mourvillier B., et al. Candida Colonization of the Respiratory Tract and Subsequent Pseudomonas Ventilator-Associated Pneumonia. Chest. 2006;129:110–117. doi: 10.1378/chest.129.1.110. - DOI - PubMed
    1. Haron E., Vartivarian S., Anaissie E., Dekmezian R., Bodey G.P. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltim.) 1993;72:137–142. doi: 10.1097/00005792-199305000-00001. - DOI - PubMed
    1. El-Ebiary M., Torres A., Fàbregas N., de la Bellacasa J.P., González J., Ramirez J., del Baño D., Hernández C., de Anta M.T.J. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am. J. Respir. Crit. Care Med. 1997;156:583–590. doi: 10.1164/ajrccm.156.2.9612023. - DOI - PubMed